Noteworthy Monday Option Activity: SKYT, CLOV, HIMS

Clover Health (CLOV) saw 29,705 options contracts trade today (~3.0M underlying shares), equal to ~55.1% of its one‑month average daily volume; the most active contract was the $2.50 put expiring Jan 30, 2026 with 12,845 contracts (~1.3M shares). Hims & Hers (HIMS) recorded 82,667 contracts (~8.3M shares), ~54.9% of its one‑month ADTV, with the $38 call expiring Feb 13, 2026 showing 8,098 contracts (~809.8k shares). These large, concentrated option flows indicate heavy directional positioning that could increase near‑term stock volatility and trading interest in both healthcare names.

Analysis

Market structure: Heavy options flow (CLOV ~29,705 contracts ≈3.0M shares, 55% of ADV; HIMS ~82,667 contracts ≈8.3M shares, 55% of ADV) signals concentrated directional positioning rather than broad fundamental rotation. Direct beneficiaries are option buyers/market-makers who will delta-hedge — CLOV put activity pressures the equity to the downside into Jan‑30‑2026 expiry, HIMS call flow supports upside into Feb‑13‑2026; market-makers’ hedging can amplify moves and widen spreads in small‑cap healthcare.

Risk assessment: Tail risks include regulatory action (CMS scrutiny or carrier-level sanctions for CLOV) and reputational/operational shocks for HIMS (telehealth compliance), plus gamma-induced short squeezes around expiries. Immediate (days) risk: gamma pinning around heavily traded strikes; short-term (weeks–months): earnings/filings and IV repricing; long-term (quarters) risk: business-model viability and capital needs. Hidden dependency: large option blocks may be hedges for structured products, not pure directional trades — verify trade initiator signals; catalysts: 10‑Q/earnings, CMS releases, short‑interest prints, retail social catalysts.

Trade implications: Favor limited-risk, skew-aware option structures. For CLOV, prefer bearish put-debit spreads sized small (0.5–1% portfolio) to Jan‑30‑2026 to cap premium and avoid naked exposure; for HIMS, prefer bullish call-debit spreads into Feb‑13‑2026 to exploit call demand while selling a higher strike to fund cost. Consider a relative-value pair: long HIMS 38/50 Feb call spread vs short CLOV 2.5/1.25 Jan put spread (size matched vega/delta) to express consumer-health > meme-insurer view.

Contrarian angles: The market assumes bearish CLOV and bullish HIMS but may be misreading hedges or block trades; if CLOV put buyers are portfolio insurers, downside could be smaller than price action implies. Historical parallels: concentrated options flow in small-caps often precedes mean reversion once large expiries pass — watch IV rank and flow exhaustion. Rule: only scale positions if IV falls >10 pts or underlying confirms direction with >15–20% move post‑flow.

Key Decisions for Investors

• Establish a 0.5–1.0% net portfolio position: buy CLOV Jan‑30‑2026 2.50/1.25 put debit spread (limit premium) to capture downside while capping losses; trim if premium falls 50% within 30 days or if IV compresses >10 pts.
• Establish a 1.0–2.0% net portfolio position: buy HIMS Feb‑13‑2026 38/50 call debit spread (defined-risk bullish play) targeting >100% return if HIMS >50% move; stop‑loss at 50% premium loss or if IV drops >15%.
• Implement a pair trade: equal‑vega long HIMS 38/50 Feb call spread and short CLOV 2.50/1.25 Jan put spread sized to neutralize overall vega (net delta bias long HIMS). Rebalance after major expiries (Jan 30, Feb 13).
• Do not sell naked options or increase size >2% on either ticker until verifying trade initiator: monitor block-trade reports and options-time & sales for buyer/seller origin, and watch CLOV CMS/10‑Q filings and HIMS upcoming earnings/product updates over next 30–60 days; reduce positions if adverse regulatory language appears.